Kyowa Kirin CoKYKOF 82 PB Ratio is 1.34 as of Jun. 26, 2026, which is 27% below its 10-year median of 1.83. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $17.92 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 922 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 59.11% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Kyowa Kirin Co's share price is $14.425. Kyowa Kirin Co's Book Value per Share for the quarter that ended in Dec. 2025 was $10.75. Hence, Kyowa Kirin Co's PB Ratio of today is 1.34.
The historical rank and industry rank for Kyowa Kirin Co's PB Ratio or its related term are showing as below:
KYKOF'
s PB Ratio Range Over the Past 10 Years
Min: 1.27 Med: 1.83 Max: 3.14
Current: 1.47
During the past 13 years, Kyowa Kirin Co's highest PB Ratio was 3.14. The lowest was 1.27. And the median was 1.83.
KYKOF's PB Ratio is ranked better than 59.11% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs KYKOF: 1.47
During the past 12 months, Kyowa Kirin Co's average Book Value Per Share Growth Rate was 5.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 4.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Kyowa Kirin Co was 16.60% per year. The lowest was -1.00% per year. And the median was 4.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Kyowa Kirin Co PB Ratio Related Terms
Kyowa Kirin Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Kyowa Kirin Co's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Kyowa Kirin Co (KYKOF) has a PB Ratio of 1.34 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kyowa Kirin Co and its competitors. This is 27% below median its historical median of 1.83. Over the past decade, Kyowa Kirin Co's PB Ratio has ranged from 1.27 to 3.14. According to the industry distribution chart, Kyowa Kirin Co ranks #377 out of 922 companies in the Drug Manufacturers industry, placing it in the top 40.9%.
Is Kyowa Kirin Co's PB Ratio too high?
Kyowa Kirin Co's current PB Ratio of 1.34 is 27% below median its 10-year median of 1.83. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 3.14. The Drug Manufacturers industry median PB Ratio is 1.83. Kyowa Kirin Co's value of 1.34 is 26.6% below this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #377 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #377 out of 922 companies for PB Ratio. This puts Kyowa Kirin Co in the upper half of its industry. The industry median PB Ratio is 1.83. Kyowa Kirin Co's value of 1.34 is 26.6% below this benchmark. Historically, Kyowa Kirin Co's own PB Ratio has ranged from 1.27 to 3.14 over the past decade. While the company's 10-year median is 1.83 vs. the industry median of 1.83, Kyowa Kirin Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current PB Ratio of 1.34 is 26.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current PB Ratio is 1.34, which is 27% below median its own 10-year median of 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $17.92, compared to a current price of $14.43 — trading 19.5% below its estimated fair value. The current PB Ratio is 1.34, which is 27% below median its 10-year median of 1.83 and 26.6% below the Drug Manufacturers industry median of 1.83. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current PB Ratio is 1.34 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 19.5% below its estimated GF Value™ of $17.92.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for KYKOF:
PB Ratio: 1.34 (27% below median its 10-year median of 1.83)
GF Value™: $17.92 vs. price of $14.43 (19.5% below fair value)
Industry Position: 26.6% below the Drug Manufacturers median (#377 of 922)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score
Get the complete analysis for KYKOF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
